Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
news icon
Repligen Releases Inaugural Sustainability Report
external link icon
Repligen Announces Conference Call to Discuss Fiscal Year 2011 Financial Results and Update Fiscal Year 2012 Financial Expectations and Corporate Strategy
news icon
Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application.
news icon
Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application
external link icon
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665 million WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) and first half (H1) of 2023, covering the three- and six-month fiscal periods ended June 30, 2023. Provided in this press release are financial performance highlights, updates to our guidance for the year 2023 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer of Repligen said, “2023 continues to be a challenging year for bioprocessing. Our base business performance in the second quarter and first half of 2023 held up reasonably well with base revenues down 9% and 3% respectively. Our Analytics, Proteins
external link icon
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year) Strong organic revenue growth of 29% and strong base business growth of 41% for the quarter Revenue guidance raised to $790 - $810 million for full year 2022
WALTHAM, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter ended June 30, 2022. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2022, updates to our financial guidance for the year 2022 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m very pleased with our performance for the second quarter where we generated $208 million in revenue, representing 29% year-over-year organic growth. We continue to
external link icon
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reported revenue was $163.0 million for the quarter, representing year-over-year growth of 86% and organic growth of 69%
Revenue guidance raised to $625-$645 million for full year 2021 Acquisition of hollow fiber innovator Polymem S.A. completed July 1, 2021
WALTHAM, Mass., July 27, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2021. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2021, updates to our financial guidance for the fiscal year 2021 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We delivered an outstanding second quarter and first half of the year for the Company, with strength across the board in all our franchises. During the second quarter, our filtration revenue more than
external link icon
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $87.5 million
Overall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth Completes acquisition of silicone molding and tubing manufacturer Engineered Molding Technology WALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m pleased to report that the company delivered outstanding financial performance during the second quarter as we continue to focus on keeping all our
external link icon
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth Completes acquisition of process analytics innovator C Technologies Closes follow-on equity and convertible debt offerings for net proceeds of $599 million WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2019. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2019, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are very pleased with the company’s performance during the second quarter, which included record revenue and 46%
external link icon
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
Complements Stainless Steel ATF Technology with Innovative Single-Use Format Improves Ease of Use for Biopharmaceutical Manufacturing Customers Offers Equivalent High Performance to Stainless Steel XCell™ ATF With Faster Implementation WALTHAM, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its single-use version of XCell™ ATF, a proprietary cell retention system used by biologic drug manufacturers to intensify cell culture and improve the efficiency and productivity of upstream processes. This innovative new single-use format, which will be offered alongside the existing stainless steel line, significantly reduces implementation time and improves overall ease of use for Repligen’s biopharmaceutical manufacturing customers. The new XCell ATF format aligns with single-use and continuous processing workflows that biomanufacturers are increasingly